본문으로 건너뛰기
← 뒤로

Gilteritinib in an Isolated CNS Recurrence of FLT3-ITD Positive AML.

증례보고 1/5 보강
Clinical case reports 📖 저널 OA 100% 2021: 7/7 OA 2022: 13/13 OA 2023: 12/12 OA 2024: 12/12 OA 2025: 45/45 OA 2026: 72/72 OA 2021~2026 2026 Vol.14(1) p. e71541 OA
Retraction 확인
출처

Silva-Bermudez LS, Streuer A, Christodoulou F, Eisele P, Steiner L, Metzgeroth G, Platten M, Hofmann WK, Abba ML

📝 환자 설명용 한 줄

Central nervous system (CNS) involvement in adult acute myeloid leukemia (AML) is uncommon and more frequently observed at relapse than at initial presentation.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Silva-Bermudez LS, Streuer A, et al. (2026). Gilteritinib in an Isolated CNS Recurrence of FLT3-ITD Positive AML.. Clinical case reports, 14(1), e71541. https://doi.org/10.1002/ccr3.71541
MLA Silva-Bermudez LS, et al.. "Gilteritinib in an Isolated CNS Recurrence of FLT3-ITD Positive AML.." Clinical case reports, vol. 14, no. 1, 2026, pp. e71541.
PMID 41550394 ↗
DOI 10.1002/ccr3.71541

Abstract

Central nervous system (CNS) involvement in adult acute myeloid leukemia (AML) is uncommon and more frequently observed at relapse than at initial presentation. Typically, CNS relapse coincides with systemic disease, evidenced by detectable blasts in the bone marrow (BM) and/or peripheral blood. We describe a rare case of an 82-year-old patient with a history of AML, diagnosed three and a half years earlier, who developed an isolated CNS relapse while receiving palliative chemotherapy-without concurrent BM involvement or molecular evidence of systemic progression. Cerebrospinal fluid (CSF) analysis revealed blast cells harboring an FLT3 internal tandem duplication (FLT3-ITD). Targeted therapy with an FLT3 tyrosine kinase inhibitor (TKI) achieved complete remission, with clearance of FLT3-ITD from the CSF.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기